Kiniksa Pharmaceuticals International (KNSA) Total Non-Current Liabilities (2018 - 2026)

Kiniksa Pharmaceuticals International's Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $194.3 million for Q1 2026.

• Quarterly Total Non-Current Liabilities rose 42.12% year-over-year to $194.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $194.3 million (up 42.12% YoY) and the FY2025 annual result came in at $177.5 million, up 26.52% from the prior year.
• Total Non-Current Liabilities was $194.3 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $177.5 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $194.3 million in Q1 2026 and bottomed at $50.9 million in Q1 2023.
• A 5-year average of $106.8 million and a median of $85.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 95.45% — and 2023, when it decreased 21.05%.
• Kiniksa Pharmaceuticals International's Total Non-Current Liabilities stood at $61.7 million in 2022, then soared by 38.81% to $85.6 million in 2023, then soared by 63.85% to $140.3 million in 2024, then increased by 26.52% to $177.5 million in 2025, then climbed by 9.45% to $194.3 million in 2026.
• Business Quant data shows KNSA's Total Non-Current Liabilities at $194.3 million in Q1 2026, $177.5 million in Q4 2025, and $162.4 million in Q3 2025.